Norwegian Government Grants Funds for Development of Flow Cytometry-Based Biomarker, Nanobusiness, published on June 1, 2011. By Cameron Chai http://www.azonano.com/news.aspx?newsID=22568

The Research Council of Norway has granted an amount of 14 million NOK to Clavis Pharma towards the research and development of the equilibrative nucleoside transporter (hENT1) biomarker. Once inside the cell the lipid tail of the LVT drug is cleaved off and the parent drug is released. With the lack of hENT1 transporter the drug is trapped inside the cell.

The company is involved in creating a flow cytometry technique for the detection and quantification of the hENT1 biomarker which is used for patients affected by acute myeloid leukemia (AML). The research is intended to design an analytical technique that would aid in selecting patients suffering from AML, who would derive maximum benefit when treated with the cancer fighting drug, elacytarabine, from Clavis.